Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 92

1.

Small cell carcinoma of the urinary bladder with hypercalcemia.

Sendur MA, Aksoy S, Arık Z, Yaman S, Ozdemir NY, Uncu D, Zengin N.

Med Oncol. 2012 Jun;29(2):827-8. doi: 10.1007/s12032-011-9947-3. No abstract available.

PMID:
21499925
[PubMed - indexed for MEDLINE]
2.

Cisplatin as an active treatment in zoledronate-refractory hypercalcemia.

Lin PH, Chiu CF, Lu YS.

Ann Oncol. 2011 May;22(5):1244-6. doi: 10.1093/annonc/mdr123. Epub 2011 Apr 2. No abstract available.

PMID:
21460375
[PubMed - indexed for MEDLINE]
Free Article
3.

[A case report of a patient treatable by home palliative care, administered zoledronic acid used for bladder cancer with hypercalcemia].

Murakami N, Tanabe K, Murasugi K, Kadoya S, Matsumoto Y, Yoshii I, Fujikawa Y, Ohura F.

Gan To Kagaku Ryoho. 2010 May;37(5):939-42. Japanese.

PMID:
20495334
[PubMed - indexed for MEDLINE]
4.

Hypercalcemia and gallium nitrate.

Gucalp R.

J Support Oncol. 2004 Nov-Dec;2(6):518-20. No abstract available.

PMID:
16329218
[PubMed - indexed for MEDLINE]
5.

[Preclinical and clinical profile of zoledronic acid (Zometa) for hypercalcemia of malignancy].

Tomoo T, Suzuki M.

Nihon Yakurigaku Zasshi. 2005 Nov;126(5):353-7. Review. Japanese. No abstract available.

PMID:
16394581
[PubMed - indexed for MEDLINE]
6.

Mismanagement of malignant hypercalcaemia.

Lightowlers S, Patterson D.

Clin Med. 2013 Feb;13(1):118. No abstract available.

PMID:
23472518
[PubMed - indexed for MEDLINE]
7.

Hypercalcemia of malignancy remains a clinically relevant problem.

Van Poznak C.

Cancer J. 2006 Jan-Feb;12(1):21-3. No abstract available.

PMID:
16613658
[PubMed - indexed for MEDLINE]
8.

Successful treatment of metastatic small cell carcinoma of the bladder with methotrexate, vinblastine, doxorubicin and cisplatin therapy.

Cheng DL, Unger P, Forscher CA, Fine EM.

J Urol. 1995 Feb;153(2):417-9.

PMID:
7815604
[PubMed - indexed for MEDLINE]
9.

[Clinical study of zoledronic acid in the treatment of cancer-induced hypercalcemia].

Shen G, Song ST, Jiang ZF, Bian SG, Xie GR, Wang YJ, Wang JJ.

Zhonghua Zhong Liu Za Zhi. 2005 Oct;27(10):632-4. Chinese.

PMID:
16438878
[PubMed - indexed for MEDLINE]
10.

Modern management of malignant hypercalcemia.

Legrand SB.

Am J Hosp Palliat Care. 2011 Nov;28(7):515-7. doi: 10.1177/1049909111414164. Epub 2011 Jul 1. Review.

PMID:
21724679
[PubMed - indexed for MEDLINE]
11.

Primary pure small cell carcinoma of the urinary bladder that responded to carboplatin plus etoposide: a case report and review of the literature.

Kaya AO, Coskun U, Yildiz R, Gonul II, Karagulle K, Yaman E, Ozturk B.

J BUON. 2009 Oct-Dec;14(4):703-6.

PMID:
20148466
[PubMed - indexed for MEDLINE]
12.

Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer.

Saad F, Eastham JA.

Semin Oncol. 2010 Jun;37 Suppl 1:S38-44. doi: 10.1053/j.seminoncol.2010.06.001. Review.

PMID:
20682371
[PubMed - indexed for MEDLINE]
13.

Successful management of small cell carcinoma of the bladder with cisplatin and etoposide.

Davis MP, Murthy MS, Simon J, Wise H, Minton JP.

J Urol. 1989 Sep;142(3):817.

PMID:
2549274
[PubMed - indexed for MEDLINE]
14.

Small cell carcinoma of the bladder: a case report and a literature review.

Dalpiaz O, al Rabi N, Galfano A, Martignoni G, Ficarra V, Artibani W.

Arch Esp Urol. 2003 Mar;56(2):197-202. Review.

PMID:
12731451
[PubMed - indexed for MEDLINE]
15.

Effective salvage treatment of recurrent Ewing sarcoma utilizing chemotherapy and zoledronic acid.

Siddiqui T, Marsh Rde W, Allegra C, Whittaker D, Scarborough M, Gibbs P, Zlotecki R, Reith JD, Drane W.

Clin Adv Hematol Oncol. 2010 Jul;8(7):499-504. No abstract available.

PMID:
20864918
[PubMed - indexed for MEDLINE]
16.

Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid.

Terpos E, Christoulas D, Kokkoris P, Anargyrou K, Gavriatopoulou M, Migkou M, Tsionos K, Dimopoulos MA.

Ann Oncol. 2010 Jul;21(7):1561-2. doi: 10.1093/annonc/mdq259. Epub 2010 May 23. No abstract available.

PMID:
20497962
[PubMed - indexed for MEDLINE]
Free Article
17.

Changes of bone resorption marker (NTX) in chemotherapy plus zoledronic acid versus chemotherapy alone for nasopharyngeal cancer patients with bone metastases.

Zhao YY, Xue C, Hou X, Liao H, Li S, Zhao HY, Huang Y, Chen LK, Xu F, Liu JL, Zhang L.

Eur J Cancer. 2011 Apr;47(6):848-53. doi: 10.1016/j.ejca.2010.12.004. Epub 2011 Jan 20.

PMID:
21256000
[PubMed - indexed for MEDLINE]
18.

[Small cell carcinoma of the urinary bladder: a case report].

Yokoyama S, Tsutahara K, Fukuhara S, Mori N, Hara T, Yamaguchi S, Adachi S.

Hinyokika Kiyo. 2005 Jun;51(6):403-5. Japanese.

PMID:
16050481
[PubMed - indexed for MEDLINE]
19.

[Efficacy of zoledronic acid combined with chemotherapy in treatment of skeletal metastases of non-small cell lung cancer and the bone metabolic markers].

Hu XY, Zou QF, Jin C, Li WD, Chen WS, Ma L.

Nan Fang Yi Ke Da Xue Xue Bao. 2010 Jun;30(6):1343-6. Chinese.

PMID:
20584674
[PubMed - indexed for MEDLINE]
Free Article
20.

The Medical Research Council Myeloma IX Trial: new clinical insights on the anticancer effects of zoledronic acid in patients with multiple myeloma.

Berenson JR.

Clin Lymphoma Myeloma Leuk. 2012 Feb;12(1):2-4. doi: 10.1016/j.clml.2011.03.025. Epub 2011 May 4. No abstract available.

PMID:
22130220
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk